Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Lamictal's New Warning On Aseptic Meningitis May Help Pfizer's Lyrica

This article was originally published in The Pink Sheet Daily

Executive Summary

On-patent antiepileptics may have another arrow in their promotional quivers after the now-generic lamotrigine gets a label update with reports of 40 cases of aseptic meningitis.

You may also be interested in...



Historical Controls For Epilepsy Studies To Be Considered By Advisory Cmte.

GlaxoSmithKline's Lamictal XR and several drugs in the pipeline could see their quest for monotherapy indications affected by what the Peripheral and Central Nervous System Drugs Advisory Committee decides.

Historical Controls For Epilepsy Studies To Be Considered By Advisory Cmte.

GlaxoSmithKline's Lamictal XR and several drugs in the pipeline could see their quest for monotherapy indications affected by what the Peripheral and Central Nervous System Drugs Advisory Committee decides.

FDA Opts For MedGuide, Not Black Box For Anti-Epileptic Suicidality

FDA has made a decision on how to communicate the suicidality risk for anti-epileptic drugs: with the first novel approvals in that class since an advisory committee on the topic, FDA has opted for a Medication Guide over a "black box" warning

Topics

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel